Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to stop muscle loss while shedding pounds

NCT ID NCT07101939

Disease control Sponsor: Actimed Therapeutics Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a drug called ACM-001.1 can help obese people keep their muscle while taking semaglutide for weight loss, and help them regain muscle after stopping semaglutide. About 120 participants will receive either ACM-001.1 or a placebo alongside semaglutide, and changes in muscle mass will be measured using DEXA scans. The goal is to find a way to lose fat without losing muscle.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
(S)-pindolol benzoate (ACM-001.1)
What this could lead to
If it works, this could lead to a way to lose weight without losing muscle, and help people regain muscle after stopping weight-loss drugs.
What could go wrong
This is an early phase 2 trial with only 120 people, so results may not apply to everyone. The drug may not work as hoped or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: Eligible for treatment with semaglutide. Have a BMI of ≥30.0 kg/m². Key Exclusion Criteria: Type 2 diabetes mellitus who in the preceding 90 days have either: * received a GLP-1RA (including semaglutide), * had a hypoglycaemic event, * lost \>5 kg weight, * had a HBA1C over 10.0%. Any cardiovascular event within previous 6 months, uncontrolled hypertension, known congestive heart failure, or angina during the past year Known severe chronic obstructive pulmonary disease (COPD) Concomitant use of beta blockers and patients with contra indications to beta blockers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Muscle loss are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

muscular atrophy Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Muscle loss Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    7 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Clinical Hospital Center 'Dr Dragisa Misovic - Dedinje'

    RECRUITING

    Belgrade, Serbia

  • Clinical Hospital Center Bezanijska kosa

    RECRUITING

    Belgrade, Serbia

  • Klinika Za Endocrinologiju, Dijabetes I Bolesti Metabolizma

    RECRUITING

    Niš, Serbia

  • Opsta bolnica Pancevo

    RECRUITING

    Pančevo, Serbia

  • University Clinical Center Kragujevac

    RECRUITING

    Kragujevac, Serbia

  • University Clinical Center of Serbia

    RECRUITING

    Belgrade, Serbia

  • University Clinical Center of Vojvodina

    RECRUITING

    Novi Sad, Serbia

More trials for these conditions

Other studies related to the condition(s) this trial covers.